Annual EBITDA
$13.91 B
+$4.83 B+53.13%
31 December 2023
Summary:
AstraZeneca annual earnings before interest, taxes, depreciation & amortization is currently $13.91 billion, with the most recent change of +$4.83 billion (+53.13%) on 31 December 2023. During the last 3 years, it has risen by +$5.83 billion (+72.09%). AZN annual EBITDA is now -9.59% below its all-time high of $15.39 billion, reached on 31 December 2011.AZN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$4.10 B
-$17.00 M-0.41%
30 September 2024
Summary:
AstraZeneca quarterly earnings before interest, taxes, depreciation & amortization is currently $4.10 billion, with the most recent change of -$17.00 million (-0.41%) on 30 September 2024. Over the past year, it has increased by +$776.00 million (+23.33%). AZN quarterly EBITDA is now -17.27% below its all-time high of $4.96 billion, reached on 30 September 2011.AZN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$14.87 B
+$776.00 M+5.51%
30 September 2024
Summary:
AstraZeneca TTM earnings before interest, taxes, depreciation & amortization is currently $14.87 billion, with the most recent change of +$776.00 million (+5.51%) on 30 September 2024. Over the past year, it has increased by +$1.24 billion (+9.11%). AZN TTM EBITDA is now -9.79% below its all-time high of $16.48 billion, reached on 30 September 2011.AZN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +53.1% | +23.3% | +9.1% |
| 3 y3 years | +72.1% | +265.6% | +93.8% |
| 5 y5 years | +95.6% | +177.5% | +107.0% |
AZN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +172.1% | -8.2% | +1366.0% | at high | +207.3% |
| 5 y | 5 years | at high | +172.1% | -8.2% | +1366.0% | at high | +207.3% |
| alltime | all time | -9.6% | +1924.9% | -17.3% | +184.9% | -9.8% | +3624.8% |
AstraZeneca EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.10 B(-0.4%) | $14.87 B(+5.5%) |
| June 2024 | - | $4.12 B(-7.8%) | $14.09 B(+2.4%) |
| Mar 2024 | - | $4.47 B(+105.0%) | $13.77 B(+2.5%) |
| Dec 2023 | $13.91 B(+53.1%) | $2.18 B(-34.5%) | $13.43 B(-1.4%) |
| Sept 2023 | - | $3.33 B(-12.4%) | $13.63 B(+5.7%) |
| June 2023 | - | $3.79 B(-8.1%) | $12.89 B(+17.1%) |
| Mar 2023 | - | $4.13 B(+73.8%) | $11.02 B(+21.3%) |
| Dec 2022 | $9.09 B(+77.7%) | $2.38 B(-8.4%) | $9.08 B(+42.3%) |
| Sept 2022 | - | $2.60 B(+35.5%) | $6.38 B(+30.0%) |
| June 2022 | - | $1.92 B(-12.9%) | $4.91 B(+1.5%) |
| Mar 2022 | - | $2.20 B(-778.4%) | $4.84 B(-9.5%) |
| Dec 2021 | $5.11 B(-36.8%) | -$324.00 M(-128.9%) | $5.35 B(-30.3%) |
| Sept 2021 | - | $1.12 B(-39.1%) | $7.67 B(-10.0%) |
| June 2021 | - | $1.84 B(-31.9%) | $8.53 B(-1.8%) |
| Mar 2021 | - | $2.71 B(+35.5%) | $8.68 B(+7.4%) |
| Dec 2020 | $8.08 B(+20.4%) | $2.00 B(+1.0%) | $8.08 B(-2.5%) |
| Sept 2020 | - | $1.98 B(-1.1%) | $8.29 B(+6.4%) |
| June 2020 | - | $2.00 B(-5.1%) | $7.79 B(+11.0%) |
| Mar 2020 | - | $2.11 B(-4.4%) | $7.02 B(+4.6%) |
| Dec 2019 | $6.71 B(-5.6%) | $2.20 B(+49.1%) | $6.71 B(-6.6%) |
| Sept 2019 | - | $1.48 B(+20.3%) | $7.18 B(-0.8%) |
| June 2019 | - | $1.23 B(-31.8%) | $7.25 B(-3.2%) |
| Mar 2019 | - | $1.80 B(-32.7%) | $7.49 B(+5.3%) |
| Dec 2018 | $7.11 B(+7.4%) | $2.68 B(+73.9%) | $7.11 B(+16.4%) |
| Sept 2018 | - | $1.54 B(+4.6%) | $6.11 B(-4.4%) |
| June 2018 | - | $1.47 B(+3.2%) | $6.39 B(-1.3%) |
| Mar 2018 | - | $1.43 B(-14.9%) | $6.48 B(-2.3%) |
| Dec 2017 | $6.62 B(-9.0%) | $1.68 B(-7.9%) | $6.63 B(-17.9%) |
| Sept 2017 | - | $1.82 B(+16.9%) | $8.07 B(+2.2%) |
| June 2017 | - | $1.56 B(-1.5%) | $7.90 B(+9.1%) |
| Mar 2017 | - | $1.58 B(-49.3%) | $7.24 B(-0.5%) |
| Dec 2016 | $7.28 B(+4.5%) | $3.12 B(+89.9%) | $7.28 B(+22.7%) |
| Sept 2016 | - | $1.64 B(+82.6%) | $5.93 B(-1.8%) |
| June 2016 | - | $899.00 M(-44.4%) | $6.04 B(-11.1%) |
| Mar 2016 | - | $1.62 B(-8.9%) | $6.79 B(-2.5%) |
| Dec 2015 | $6.96 B(+26.8%) | $1.77 B(+1.5%) | $6.96 B(+18.2%) |
| Sept 2015 | - | $1.75 B(+5.9%) | $5.89 B(+6.1%) |
| June 2015 | - | $1.65 B(-7.7%) | $5.55 B(-2.9%) |
| Mar 2015 | - | $1.79 B(+155.1%) | $5.71 B(+4.1%) |
| Dec 2014 | $5.49 B(-34.2%) | $701.00 M(-50.2%) | $5.49 B(-19.4%) |
| Sept 2014 | - | $1.41 B(-22.5%) | $6.81 B(-9.3%) |
| June 2014 | - | $1.82 B(+16.3%) | $7.51 B(-4.2%) |
| Mar 2014 | - | $1.56 B(-22.8%) | $7.84 B(-6.1%) |
| Dec 2013 | $8.34 B(-21.9%) | $2.02 B(-4.0%) | $8.35 B(-7.7%) |
| Sept 2013 | - | $2.11 B(-1.8%) | $9.04 B(-8.1%) |
| June 2013 | - | $2.15 B(+3.7%) | $9.84 B(-2.4%) |
| Mar 2013 | - | $2.07 B(-23.8%) | $10.09 B(-5.6%) |
| Dec 2012 | $10.68 B(-30.6%) | $2.72 B(-6.6%) | $10.68 B(-0.3%) |
| Sept 2012 | - | $2.91 B(+21.8%) | $10.72 B(-16.0%) |
| June 2012 | - | $2.39 B(-10.4%) | $12.77 B(-8.7%) |
| Mar 2012 | - | $2.67 B(-3.2%) | $13.99 B(-9.1%) |
| Dec 2011 | $15.39 B(+4.4%) | $2.75 B(-44.5%) | $15.39 B(-6.6%) |
| Sept 2011 | - | $4.96 B(+37.3%) | $16.48 B(+12.5%) |
| June 2011 | - | $3.61 B(-11.1%) | $14.65 B(+0.1%) |
| Mar 2011 | - | $4.06 B(+5.6%) | $14.63 B(-0.8%) |
| Dec 2010 | $14.74 B(+5.7%) | $3.85 B(+22.9%) | $14.75 B(+5.4%) |
| Sept 2010 | - | $3.13 B(-12.8%) | $13.98 B(-4.5%) |
| June 2010 | - | $3.59 B(-14.0%) | $14.64 B(+1.3%) |
| Mar 2010 | - | $4.18 B(+35.4%) | $14.46 B(+3.7%) |
| Dec 2009 | $13.95 B(+10.5%) | $3.08 B(-18.6%) | $13.95 B(+0.4%) |
| Sept 2009 | - | $3.79 B(+11.2%) | $13.90 B(+3.8%) |
| June 2009 | - | $3.41 B(-6.9%) | $13.39 B(+2.5%) |
| Mar 2009 | - | $3.66 B(+20.6%) | $13.06 B(+3.5%) |
| Dec 2008 | $12.62 B | $3.04 B(-7.6%) | $12.62 B(+11.1%) |
| Sept 2008 | - | $3.29 B(+6.8%) | $11.36 B(+4.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2008 | - | $3.08 B(-4.3%) | $10.88 B(+4.8%) |
| Mar 2008 | - | $3.22 B(+80.9%) | $10.38 B(+4.3%) |
| Dec 2007 | $9.95 B(+4.1%) | $1.78 B(-36.6%) | $9.95 B(-0.3%) |
| Sept 2007 | - | $2.80 B(+8.6%) | $9.98 B(+1.5%) |
| June 2007 | - | $2.58 B(-7.4%) | $9.83 B(-2.5%) |
| Mar 2007 | - | $2.79 B(+54.0%) | $10.09 B(+5.5%) |
| Dec 2006 | $9.56 B(+22.1%) | $1.81 B(-31.9%) | $9.56 B(+2.8%) |
| Sept 2006 | - | $2.66 B(-6.4%) | $9.30 B(+2.6%) |
| June 2006 | - | $2.84 B(+25.6%) | $9.06 B(+10.4%) |
| Mar 2006 | - | $2.26 B(+46.1%) | $8.21 B(+4.8%) |
| Dec 2005 | $7.83 B(+34.6%) | $1.55 B(-36.1%) | $7.83 B(-1.2%) |
| Sept 2005 | - | $2.42 B(+21.9%) | $7.93 B(+13.7%) |
| June 2005 | - | $1.98 B(+5.5%) | $6.97 B(+9.9%) |
| Mar 2005 | - | $1.88 B(+14.5%) | $6.34 B(+8.5%) |
| Dec 2004 | $5.82 B(+9.7%) | $1.64 B(+12.3%) | $5.85 B(+10.9%) |
| Sept 2004 | - | $1.46 B(+8.0%) | $5.27 B(-2.4%) |
| June 2004 | - | $1.35 B(-2.2%) | $5.40 B(+5.6%) |
| Mar 2004 | - | $1.39 B(+29.9%) | $5.12 B(-3.4%) |
| Dec 2003 | $5.30 B(+6.7%) | $1.07 B(-33.1%) | $5.30 B(+1.9%) |
| Sept 2003 | - | $1.59 B(+48.9%) | $5.20 B(+8.7%) |
| June 2003 | - | $1.07 B(-31.7%) | $4.78 B(-4.5%) |
| Mar 2003 | - | $1.57 B(+61.8%) | $5.01 B(+0.9%) |
| Dec 2002 | $4.97 B(-1.0%) | $968.80 M(-17.7%) | $4.97 B(-6.6%) |
| Sept 2002 | - | $1.18 B(-9.2%) | $5.31 B(-0.9%) |
| June 2002 | - | $1.30 B(-15.0%) | $5.36 B(+2.7%) |
| Mar 2002 | - | $1.52 B(+15.7%) | $5.22 B(+4.4%) |
| Dec 2001 | $5.02 B(+2.1%) | $1.32 B(+7.6%) | $5.00 B(+0.5%) |
| Sept 2001 | - | $1.22 B(+6.2%) | $4.97 B(+0.7%) |
| June 2001 | - | $1.15 B(-11.5%) | $4.93 B(-1.7%) |
| Mar 2001 | - | $1.30 B(+0.9%) | $5.02 B(+2.2%) |
| Dec 2000 | $4.91 B(+9.2%) | $1.29 B(+8.7%) | $4.91 B(+11.3%) |
| Sept 2000 | - | $1.19 B(-4.3%) | $4.41 B(+0.4%) |
| June 2000 | - | $1.24 B(+3.9%) | $4.39 B(-0.7%) |
| Mar 2000 | - | $1.19 B(+50.7%) | $4.42 B(-42.9%) |
| Dec 1999 | $4.50 B(+38.5%) | $792.00 M(-32.2%) | $7.75 B(+264.3%) |
| Sept 1999 | - | $1.17 B(-7.9%) | $2.13 B(-35.3%) |
| June 1999 | - | $1.27 B(-71.9%) | $3.29 B(+13.8%) |
| Mar 1999 | - | $4.52 B(-193.6%) | $2.89 B(+268.0%) |
| Dec 1998 | $3.25 B(+44.7%) | -$4.83 B(-307.3%) | $785.10 M(-34.9%) |
| Sept 1998 | - | $2.33 B(+168.1%) | $1.21 B(+23.7%) |
| June 1998 | - | $869.00 M(-64.1%) | $975.55 M(-59.2%) |
| Mar 1998 | - | $2.42 B(-154.8%) | $2.39 B(+5.9%) |
| Dec 1997 | $2.24 B(+4.4%) | -$4.41 B(-310.1%) | $2.26 B(-40.9%) |
| Sept 1997 | - | $2.10 B(-8.1%) | $3.82 B(-5.3%) |
| June 1997 | - | $2.28 B(0.0%) | $4.03 B(+0.1%) |
| Mar 1997 | - | $2.28 B(-180.2%) | $4.03 B(+0.1%) |
| Dec 1996 | $2.15 B(+59.1%) | -$2.85 B(-223.1%) | $4.02 B(+89.9%) |
| Sept 1996 | - | $2.31 B(+1.5%) | $2.12 B(+21.8%) |
| June 1996 | - | $2.28 B(0.0%) | $1.74 B(-1184.3%) |
| Mar 1996 | - | $2.28 B(-147.9%) | -$160.41 M(-62.0%) |
| Dec 1995 | $1.35 B(-8.5%) | -$4.75 B(-345.6%) | -$421.81 M(-240.2%) |
| Sept 1995 | - | $1.94 B(+411.0%) | $300.94 M(+153.4%) |
| June 1995 | - | $378.70 M(-81.2%) | $118.74 M(-92.5%) |
| Mar 1995 | - | $2.02 B(-150.1%) | $1.58 B(+12.9%) |
| Dec 1994 | $1.48 B(+6.0%) | -$4.03 B(-329.9%) | $1.40 B(-8.8%) |
| Sept 1994 | - | $1.75 B(-4.6%) | $1.53 B(+16.4%) |
| June 1994 | - | $1.84 B(0.0%) | $1.32 B(+7.2%) |
| Mar 1994 | - | $1.84 B(-147.2%) | $1.23 B(+7.8%) |
| Dec 1993 | $1.39 B(+102.8%) | -$3.90 B(-353.4%) | $1.14 B(-77.4%) |
| Sept 1993 | - | $1.54 B(-12.1%) | $5.03 B(+44.0%) |
| June 1993 | - | $1.75 B(0.0%) | $3.50 B(+100.0%) |
| Mar 1993 | - | $1.75 B | $1.75 B |
| Dec 1992 | $687.06 M(-59.1%) | - | - |
| Dec 1991 | $1.68 B(+22.2%) | - | - |
| Dec 1990 | $1.37 B | - | - |
FAQ
- What is AstraZeneca annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for AstraZeneca?
- What is AstraZeneca annual EBITDA year-on-year change?
- What is AstraZeneca quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for AstraZeneca?
- What is AstraZeneca quarterly EBITDA year-on-year change?
- What is AstraZeneca TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for AstraZeneca?
- What is AstraZeneca TTM EBITDA year-on-year change?
What is AstraZeneca annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AZN is $13.91 B
What is the all time high annual EBITDA for AstraZeneca?
AstraZeneca all-time high annual earnings before interest, taxes, depreciation & amortization is $15.39 B
What is AstraZeneca annual EBITDA year-on-year change?
Over the past year, AZN annual earnings before interest, taxes, depreciation & amortization has changed by +$4.83 B (+53.13%)
What is AstraZeneca quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AZN is $4.10 B
What is the all time high quarterly EBITDA for AstraZeneca?
AstraZeneca all-time high quarterly earnings before interest, taxes, depreciation & amortization is $4.96 B
What is AstraZeneca quarterly EBITDA year-on-year change?
Over the past year, AZN quarterly earnings before interest, taxes, depreciation & amortization has changed by +$776.00 M (+23.33%)
What is AstraZeneca TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AZN is $14.87 B
What is the all time high TTM EBITDA for AstraZeneca?
AstraZeneca all-time high TTM earnings before interest, taxes, depreciation & amortization is $16.48 B
What is AstraZeneca TTM EBITDA year-on-year change?
Over the past year, AZN TTM earnings before interest, taxes, depreciation & amortization has changed by +$1.24 B (+9.11%)